Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Thomas Jefferson University
University of Wisconsin, Madison
Yale University
UNICANCER
Rutgers, The State University of New Jersey
The Methodist Hospital Research Institute
The Methodist Hospital Research Institute
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
The Methodist Hospital Research Institute
University of Texas Southwestern Medical Center
Medstar Health Research Institute
City of Hope Medical Center
Xijing Hospital
Montefiore Medical Center
Cedars-Sinai Medical Center
Albert Einstein College of Medicine
Montefiore Medical Center
Weill Medical College of Cornell University
Masonic Cancer Center, University of Minnesota
SCRI Development Innovations, LLC
Wake Forest University Health Sciences
Mayo Clinic
Providence Health & Services
SCRI Development Innovations, LLC
SCRI Development Innovations, LLC
Consorzio Oncotech
Accelerated Community Oncology Research Network
University of Southern California
University of Chicago
University of Alabama at Birmingham
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
UNC Lineberger Comprehensive Cancer Center
Chang Gung Memorial Hospital
Hellenic Cooperative Oncology Group